Tumor-Homing Peptides as Crucial Component of Magnetic-Based Delivery Systems: Recent Developments and Pharmacoeconomical Perspective

Int J Mol Sci. 2024 Jun 5;25(11):6219. doi: 10.3390/ijms25116219.

Abstract

According to data from the World Health Organization (WHO), cancer is considered to be one of the leading causes of death worldwide, and new therapeutic approaches, especially improved novel cancer treatment regimens, are in high demand. Considering that many chemotherapeutic drugs tend to have poor pharmacokinetic profiles, including rapid clearance and limited on-site accumulation, a combined approach with tumor-homing peptide (THP)-functionalized magnetic nanoparticles could lead to remarkable improvements. This is confirmed by an increasing number of papers in this field, showing that the on-target peptide functionalization of magnetic nanoparticles improves their penetration properties and ensures tumor-specific binding, which results in an increased clinical response. This review aims to highlight the potential applications of THPs in combination with magnetic carriers across various fields, including a pharmacoeconomic perspective.

Keywords: anticancer therapy; clinical analysis; cost-effectiveness analysis; delivery systems; pharmacoeconomics; targeted delivery; targeting ligands; tumor-homing peptides.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents* / administration & dosage
  • Antineoplastic Agents* / chemistry
  • Antineoplastic Agents* / therapeutic use
  • Drug Carriers / chemistry
  • Drug Delivery Systems / methods
  • Economics, Pharmaceutical
  • Humans
  • Magnetite Nanoparticles / chemistry
  • Magnetite Nanoparticles / therapeutic use
  • Neoplasms* / drug therapy
  • Peptides* / chemistry

Substances

  • Peptides
  • Antineoplastic Agents
  • Magnetite Nanoparticles
  • Drug Carriers